PI3K/Akt/mTOR inhibitors in breast cancer
Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition of the pathway, and phase I to III trials involving inhibitors of the pathway have been or are being conducted in solid tumo...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Chinese Anti-Cancer Association
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4706528/ |